In the early trading session on Thursday, the stock of Strides Pharma Science was trading in green after the company made an announcement that its wholly-owned subsidiary, Strides Pharma Global Private Limited was granted regulatory approval by United States Food and Drug Administration (USFDA) for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate capsules of 50 mg/325 mg/40 mg/30 mg.